Alice Zhang Headshot
Report a problem with this profile
[email protected]

Alice Zhang      

Cofounder, Verge Genomics

Alice Zhang is the Cofounder of Verge Genomics, a company that utilizes the exponential advances in computational genomics combined with new insights into neuroscience to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.

Zhang has been at the forefront of systems biology research for over seven years, at the National Cancer Institute, the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and UCLA. During this time, she has co-authored four peer-reviewed papers in high profile journals such as Cell and Neuron.

She graduated from Princeton University magna cum laude with high honors in Molecular Biology and is a 2012 recipient of the prestigious Paul & Daisy Soros Fellowship for New Americans. In 2010, she began training in the UCLA-Caltech MD/Ph.D. program, with a focus in neuroscience, where she spent five years investigating gene networks involved in neuro-regeneration. She was recently named as a Forbes 2017 30 Under 30 Featured Honoree.

News


No PhD, “No Fear”: Alice Zhang, 27, Aims Software At Neuro Diseases

It’s impossible to sum up a person with a word, a sentence, or even a paragraph. We all contain multitudes. But if a picture of 27-year-old biotech CEO Alice Zhang could emerge from a single line, it might be her response when asked to describe her first time through the whirlwind of the annual J.P. Morgan healthcare conference in San Francisco...

CEO Alice Zhang speaks about Verge Genomics on "Targeting Orphan Diseases" panel

Verge Genomics CEO Alice Zhang was invited to speak on a panel featuring industry-leading biotechnology companies focused on orphan disease drug discovery at the annual Neurotech Investing & Partnering Conference. At the panel, Zhang discussed her experience co-founding and leading Verge Genomics and the Company's progress in its lead program in ALS. The panel focused on successful R&D strategies for addressing smaller rare disease markets...

Verge Genomics Completes Initial Financing to Discover and Develop Treatments for Neurodegenerative Diseases Using Genomic Data

Verge Genomics, Inc. (Verge), a privately held biopharmaceutical company focused on neurodegenerative diseases, announced today that it has completed a seed financing totaling $4 million. IA Ventures led the syndicate, which included Two Sigma Ventures, Draper Associates, Great Oaks VC, Slow Ventures, Karlin Ventures and private investors. Verge was recently launched through the prestigious YCombinator accelerator program...

Related Speakers View all


More like Alice